Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from managed care entities. Such insurers are frequently creating barriers to coverage, such as steep cost restrictions and PA that restrict consumer access. Analysts suggest that s